NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
Clinical Trials
19 trialsNCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT01505868 2021-07-30
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01757171 2018-04-03
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01438307 2017-05-24
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT01447225 2016-09-14
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
Phase 1 Completed
NCT01751308 2016-08-12
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Sanofi
Phase 1/2 Completed
NCT01500720 2015-04-13
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT00417079 2011-03-10
TROPIC
Sanofi
Phase 3 Completed